Insulet Reports 28.8% Q1 Revenue Growth, Shares Rise 7%

Insulet Corporation reported strong first-quarter 2025 results, with revenue rising 28.8% year over year to $569 million, surpassing analyst expectations. The company's Omnipod insulin pumps, including the advanced Omnipod 5 device cleared for managing both type 1 and type 2 diabetes, drove this growth and accounted for $554.1 million in sales. Insulet raised its revenue growth forecast to 19%–22%, up from the previous 16%–20%, despite concerns about competition from GLP-1 diabetes and weight-loss drugs. The company’s operating margin improved to 15.6%, and adjusted earnings per share beat estimates at $1.02. New CEO Ashley McEvoy expressed confidence in transforming Insulet into a consistent growth leader in diabetes management, with analysts generally optimistic, reflected in an average price target suggesting over 20% upside. This strong performance and innovation emphasize Insulet's growing influence in the diabetes care market amid broader healthcare technology advancements.